SAN DIEGO, California — A novel liposomal formulation of cytarabine and daunorubicin, known as CPX-351 (Vyxeos, Jazz Pharmaceuticals), has again been shown to be superior to a standard version of this ...
** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** When Joe Roebuck established his ...
PRINCETON, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals today announced positive clinical data in elderly patients with newly-diagnosed acute myeloid leukemia (AML) treated with CPX-351 ...
IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study. First-in class selective AXL ...
Celator announced the completion of enrollment for its Phase 2 study of CPX-351 (cytarabine and daunorubicin) Liposome Injection for the treatment of adult patients with acute myeloid leukemia (AML).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results